The Pharmaceutical Market: China

Date: January 31, 2013
Pages: 118
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P4425B52B73EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: China
OVERVIEW OF THE PHARMACEUTICAL MARKET IN CHINA

We remain bullish on China's pharmaceutical sector despite the slowdown in the economy and political reshuffle. We do not think the reshuffle will have any adverse changes or cause any reversals to healthcare reform given that the country has been rolling out various healthcare schemes in 2012 and that a key person overseeing these healthcare reform plans is Vice Premier Li Keqiang, the man who may potentially take over from Premier Wen Jiabao in the reshuffle. However, the business environment will potentially be threaten by cost- containment policies as the country will have to contain its ever-growing healthcare expenditure.

Headline Expenditure Projections

Pharmaceuticals: CNY432bn (US66.7bn) in 2011to CNY521bn (US$82.2bn) in 2012; +20.6% in local currency and +23.0% in US dollar terms. Forecast broadly in line with Q 4 12.

Healthcare: CNY2313bn (US$358bn) in 2011 to CNY2,602bn (US$410bn) in 2012; +12.5% in local currency terms and +14.7% in US dollar terms. Forecast broadly in line with Q 4 12.

Medical Devices: CNY117bn (US$18.2bn) in 2011 to CNY146bn (US$22.8bn) in 2012; +24.3% in local currency terms and +26.7% in US dollar terms. Forecast broadly in line with Q 4 12.

Risk/Reward Rating: China continues to rank fourth out of the 18 key markets in BMI's Q113 Asia Pacific Pharmaceutical Risk/Reward Ratings with an unchanged score of 62.5 Its high ranking on the table (just behind developed markets Japan, South Korea and Australia) is largely due to the strong growth potential of the pharmaceutical market that is underpinned by a large and increasingly affluent population and an increasing burden of non-communication diseases.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

      China Pharmaceuticals And Healthcare Industry SWOT
      China Political SWOT
      China Economic SWOT
      China Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

      Table: Asia Pacific Pharmaceutical And Healthcare RRRs, Q113
      Rewards
      Risks

MARKET SUMMARY

REGULATORY REGIME

      Intellectual Property Issues
      Administrative Protection
      Counterfeit Medicines
      Pricing Regime
      Price Cuts
      Reimbursement Regime

INDUSTRY TRENDS AND DEVELOPMENTS

      Epidemiology
      Communicable Diseases
      Non-Communicable Diseases
      Healthcare Sector
      Hospital Sector
      R&D Activity
      Table: Selected List Of MNC With R&D Bases In China
      Clinical Trials Activity
      Active Pharmaceutical Ingredients
      Vaccine Sector

INDUSTRY FORECAST SCENARIO

  Overall Market Forecast
      Table: Pharmaceutical Sales Indicators 2008-2016
  Key Growth Factors – Industry
      Table: Healthcare Expenditure Indicators 2008-2016
      Table: Healthcare Governmental Indicators 2008-2016
      Table: Healthcare Private Indicators 2008-2016
  Key Growth Factors – Macroeconomic Forecast
      Table: Economic Activity
  Prescription Drug Market Forecast
      Table: Prescription Drug Sales Indicators 2008-2016
  Patented Drug Market Forecast
      Table: Patented Drug Market Indicators 2008-2016
  Generic Drug Market Forecast
      Table: Generic Drug Sales Indicators 2008-2016
  OTC Medicine Market Forecast
      Table: OTC Medicine Sales Indicators 2008-2016
  Medical Device Market Forecast
      Table: Medical Devices Sales Indicators 2008-2016
  Pharmaceutical Trade Forecast
      Table: Exports and Imports Indicators 2009-2016
  Other Healthcare Data Forecasts
  Key Risks To BMI's Forecast Scenario

COMPETITIVE LANDSCAPE

      Pharmaceutical Industry
      Table: Top 20 China Or Hong Kong-Based Pharmaceutical Companies According To Market Capitalisation
      Pharmaceutical Wholesale
      Recent Pharmaceutical Industry Developments
      Traditional Chinese Medicine

COMPANY PROFILES

  Leading Local Companies
      Sinopharm
      China Shijiazhuang Pharmaceutical Group (CSPC)
      North China Pharmaceutical Corporation (NCPC)
      Shanghai Pharmaceutical
  Leading Multinational Companies
      GlaxoSmithKline
      Pfizer
      AstraZeneca
      Merck KGaA
      Sanofi
      Novartis
      Roche
      Eli Lilly (Lilly China)
      Merck & Co
      Bayer Schering Pharma

DEMOGRAPHIC OUTLOOK

      Table: China's Population By Age Group, 1990-2020 ('000)
      Table: China's Population By Age Group, 1990-2020 (% of total)
      Table: China's Key Population Ratios, 1990-2020
      Table: China's Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

  How We Generate Our Pharmaceutical Industry Forecasts
      Risk/Reward Ratings Methodology
      Ratings Overview
      Table: Pharmaceutical Business Environment Indicators
      Weighting
      Table: Weighting Of Components
Skip to top


Looking at Offshoring in the Pharmaceutical Industry US$ 300.00 Jun, 2011 · 50 pages
The Pharmaceutical Market: Taiwan US$ 1,295.00 Jan, 2013 · 108 pages
The Pharmaceutical Market: Colombia US$ 1,295.00 Jan, 2013 · 114 pages

Ask Your Question

The Pharmaceutical Market: China
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: